不同剂量替罗非班对急性冠脉综合征患者PCI术后疗效及安全性观察

Curative effect and safety of tirofiban in different doses in patients with acute coronary syndrome after PCI

目的研究不同剂量替罗非班对急性冠脉综合征患者经皮冠状动脉介入治疗(PCI)术后疗效及安全性。方法选择2016年1月至2019年12月于解放军总医院第一医学中心诊断为急性冠脉综合征(ACS)且接受直接PCI治疗的661例患者作为研究对象进行作回顾性分析。根据治疗方法不同,将患者分为替罗非班常规剂量组(346例)及替罗非班低剂量组(315例),对比两组患者的基线数据、出血事件、缺血事件及主要不良心血管事件(MACE)发生率情况。结果两组患者的基线数据无统计学差异,与常规剂量组相比,替罗非班低剂量组不增加患者出血事件(P=0.274),缺血事件(P=0.324)及MACE事件(P=0.208)发生风险。结论ACS患者PCI围手术期应用低剂量替罗非班具有较好的安全性与可靠性。

Objective To study the curative effect and safety of tirofiban in different doses in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods ACS patients undergone PCI(n=661)were chosen from the First Medical Center of Chinese PLA General Hospital from Jan.2016 to Dec.2019 and given retrospective analysis.All patients were divided,according to different therapies,into routine-dose tirofiban group(n=346)and low-dose tirofiban group(n=315).The baseline data and incidence rates of bleeding events,ischemic events and major adverse cardiovascular events(MACE)were compared between 2 groups.Results The baseline data had no statistical difference between 2 groups.The risks of bleeding events(P=0.274),ischemic events(P=0.324)and MACE(P=0.208)did not increase in low-dose tirofiban group compared with those in routine-dose tirofiban group.Conclusion During peri-PCI period low-dose tirofiban has higher safety and reliability in ACS patients.